Unexpected toxicity of combination thalidomide and interferon alfa-2a treatment in metastatic renal cell carcinoma

被引：29

作者：

Nathan, PD ^{[1
]}

Gore, ME ^{[1
]}

Eisen, TG ^{[1
]}

机构：

[1] Royal Marsden Hosp, Sutton, Surrey, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2002年 / 20卷 / 05期

关键词：

D O I：

10.1200/JCO.2002.20.5.1429

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1429 / 1430

页数：2

共 4 条

[1] Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer [J].

Eisen, T ;

Boshoff, C ;

Mak, I ;

Sapunar, F ;

Vaughan, MM ;

Pyle, L ;

Johnston, SRD ;

Ahern, R ;

Smith, IE ;

Gore, ME .

BRITISH JOURNAL OF CANCER, 2000, 82 (04) :812-817

[2] Antitumor activity of thalidomide in refractory multiple myeloma. [J].

Singhal, S ;

Mehta, J ;

Desikan, R ;

Ayers, D ;

Roberson, P ;

Eddlemon, P ;

Munshi, N ;

Anaissie, E ;

Wilson, C ;

Dhodapkar, M ;

Zeldis, J ;

Barlogie, B ;

Siegel, D ;

Crowley, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (21) :1565-1571

[3] Thalidomide in cancer - Potential uses and limitations [J].

Singhal, S ;

Mehta, J .

BIODRUGS, 2001, 15 (03) :163-172

[4] The treatment of advanced renal cell cancer with high-dose oral thalidomide [J].

Stebbing, J ;

Benson, C ;

Eisen, T ;

Pyle, L ;

Smalley, K ;

Bridle, H ;

Mak, I ;

Sapunar, F ;

Ahern, R ;

Gore, ME .

BRITISH JOURNAL OF CANCER, 2001, 85 (07) :953-958

← 1 →